Sluggish sales growth due to intensifying competition in topical antifungal products
First written in FY2017-Q3. 9 of 27 entries say "Mitigated", first in FY2018-Q3. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「In the Pharmaceuticals business, sales of luliconazole, a topical antifungal agent, remained firm in Japan, including for onychomycosis.」
The improvement from the previous sales slump in topical antifungal agents has continued, with sales again described as firm during the period. - 2026-05-13MitigatedEarnings forecast revision
「In the Pharmaceuticals business, sales of luliconazole, a topical antifungal agent, remained firm in Japan, including for onychomycosis.」
Full-year sales of luliconazole, including for onychomycosis, remained firm, easing the previous stagnation in sales during the fiscal year. - FY2026-H1MitigatedAnnual report
「In the pharmaceutical business, sales of the topical antifungal agent luliconazole for toenail fungus and other domestic indications increased as inventory in the distribution channel was reduced and shipments to distributors accelerated, among other factors.」
Luliconazole sales increased against the backdrop of the reduction of channel inventories and faster shipments to distributors, mitigating the previous sales stagnation during the period. - FY2025ReframedAnnual report
「In the pharmaceutical business, sales of the topical antifungal agent luliconazole for toenail fungus remained sluggish due to the impact of excess inventory held by distributors.」
The explanation for the sales slump in topical antifungal agents has become more specific, shifting from competition and declining overseas demand to excess distributor inventories of toenail tinea treatments. - FY2025-H1RestatedAnnual report
「In the pharmaceutical business, sales of the topical antifungal agent luliconazole for toenail fungus remained sluggish.」
Sales of topical antifungal agents have continued to stagnate, this time described as weak sales for toenail tinea treatments. - FY2024-Q3ReframedAnnual report
「In the pharmaceutical business, sales were sluggish following the discontinuation of luliconazole sales in China.」
Sales of topical antifungal agents have continued to stagnate, with the current factor described as the termination of sales in China rather than intensified competition. - FY2024-Q2MaterialisedAnnual report
「In the pharmaceutical business, sales of the topical antifungal agent luliconazole remained sluggish due to lower overseas demand, among other factors.」
Against the backdrop of declining overseas demand, the stagnation in luliconazole sales has materialized in the results. - FY2024-Q1MaterialisedAnnual report
「In the pharmaceutical business, sales of the topical antifungal agent luliconazole remained sluggish due to lower overseas demand, among other factors.」
Luliconazole sales have stagnated again. This time, the factor is described as a decline in overseas demand rather than intensified competition. - FY2023-Q3MitigatedAnnual report
「In the pharmaceutical business, sales of topical antifungal agents remained firm.」
Against the backdrop of continued stagnation in sales of luliconazole and other products, sales of topical antifungal agents were described as firm this quarter, and the impact of the sales slump was mitigated during the period. - FY2023-Q2MaterialisedAnnual report
「In the pharmaceuticals business, sales of the topical antifungal agent luliconazole for athlete's foot treatments stagnated.」
For luliconazole, sales for athlete's foot treatments have continued to stagnate. The current disclosure indicates sales trends themselves, rather than intensified competition, as the factor. - FY2023-Q1RestatedAnnual report
「Meanwhile, in the pharmaceutical business, sales of the topical antifungal agent luliconazole remained sluggish for both athlete's foot and toenail fungus treatments.」
The stagnation in luliconazole sales has continued for both athlete's foot and toenail tinea treatments, which has been reconfirmed. - FY2022MaterialisedAnnual report
「Meanwhile, in the pharmaceutical business, sales of the topical antifungal agent luliconazole remained sluggish as the number of outpatients at medical institutions declined due to the spread of COVID-19, among other factors.」
Against the backdrop of a decline in outpatient numbers due to COVID-19, the stagnation in luliconazole sales has materialized in the results. - FY2022-Q3MaterialisedAnnual report
「Meanwhile, in the pharmaceutical business, sales of the topical antifungal luliconazole struggled to grow, partly because the number of outpatient visits to medical institutions declined as the COVID-19 pandemic spread.」
Against the backdrop of the spread of COVID-19 and a decline in outpatient numbers at medical institutions, the stagnation in luliconazole sales has materialized in the results. The current disclosure does not explicitly identify intensified competition as a factor. - FY2022-Q2MaterialisedAnnual report
「Meanwhile, in the pharmaceutical business, sales of the topical antifungal luliconazole struggled to grow.」
The stagnation in luliconazole sales has been reported as an actual result. The current disclosure does not explicitly identify intensified competition as a factor. - FY2021MitigatedAnnual report
「Meanwhile, in the pharmaceutical business, sales of the topical antifungal agents luliconazole and lanoconazole in the athlete's foot segment increased.」
Against the previous stagnation in sales due to competition and other factors, sales of both agents in the athlete's foot area were reported to have increased, with the impact mitigated during the period. - FY2021-Q1MitigatedAnnual report
「In the pharmaceutical business, sales of the topical antifungal agent luliconazole in the toenail fungus segment increased.」
Sales of luliconazole in the toenail tinea area increased, and the previous stagnation in sales due to competition and other factors was mitigated during the period. - FY2020-Q3MitigatedAnnual report
「In the pharmaceutical business, sales of the topical antifungal agents lanoconazole and luliconazole increased.」
Sales of lanoconazole and luliconazole increased, and the previous stagnation in sales caused by intensified competition was mitigated during the period. - FY2020-Q1RestatedAnnual report
「In addition, in the pharmaceutical business, sales of the topical antifungal luliconazole in the onychomycosis segment remained strong.」
Strong sales of luliconazole in the toenail tinea area have continued, reconfirming that the sales slump caused by intensified competition has been mitigated in this area. - FY2019-Q4RestatedAnnual report
「In the pharmaceutical business, sales of the topical antifungal agent luliconazole in the toenail fungus segment remained strong.」
Strong sales of luliconazole in the toenail tinea area have continued, reconfirming that the impact of the previous sales slump has been mitigated in this area. - FY2019-Q3MitigatedAnnual report
「In the pharmaceutical business, revenue from the topical antifungal luliconazole in the onychomycosis segment increased.」
Sales of luliconazole in the toenail tinea area increased, suggesting that the impact of the previous slump in sales of topical antifungal agents has been mitigated in this area. - FY2018MitigatedAnnual report
「In the pharmaceutical business, sales of the topical antifungal agent luliconazole in the toenail fungus segment remained strong.」
Strong sales in the toenail tinea area have been indicated, suggesting that the impact of the previous slump in sales of topical antifungal agents has been mitigated in this area. - FY2018-Q4ReframedAnnual report
「In the pharmaceutical business, sales of the topical antifungal luliconazole in the onychomycosis segment remained steady. However, sales in the tinea pedis segment struggled to grow, and revenue fell below the same period of the previous year.」
The explanation has changed from a general slump in sales due to intensifying competition to a segment-specific explanation: strength in the toenail tinea area and stagnant growth in the athlete's foot area. - FY2018-Q3MitigatedAnnual report
「In the pharmaceutical business, sales exceeded the same period of the previous year, supported by steady sales of the topical antifungal lanoconazole.」
Sales of lanoconazole were described as firm, along with year-on-year revenue growth in the pharmaceuticals business, indicating that the previous weakness in sales of the product had eased in the current quarter. - FY2017ReframedAnnual report
「In the pharmaceuticals business, sales of the topical antifungal agent luliconazole were strong in the tinea pedis segment. In the onychomycosis segment, sales were sluggish due to the effects of distributors' inventory carried over from previous years and other factors.」
The explanation has shifted from intensifying competition across topical antifungal products to strong performance in the tinea pedis segment and sluggish sales in the onychomycosis segment due to distributors' inventory carried over from previous years. - FY2018-Q1MaterialisedAnnual report
「Meanwhile, sales of the topical antifungal agent luliconazole in the onychomycosis segment were sluggish in the pharmaceuticals business due to intensifying sales competition and other factors.」
Against a backdrop of intensifying sales competition, sluggish sales of luliconazole in the onychomycosis segment were recorded. - FY2017-Q4MaterialisedAnnual report
「Meanwhile, in the pharmaceuticals business, sales of the topical antifungal agents lanoconazole and luliconazole fell below the same period of the previous year due to intensifying sales competition and other factors.」
Against a backdrop of intensifying sales competition, lower sales of lanoconazole and luliconazole were recorded. - FY2017-Q3First statedAnnual report
「Meanwhile, sales of the topical antifungal agent lanoconazole in the pharmaceuticals business were sluggish due to intensifying sales competition and other factors.」
Against a backdrop of intensifying sales competition, sluggish sales of the topical antifungal agent lanoconazole were recorded.